Sensei Biotherapeutics, Inc. · NASDAQ:SNSE
Sensei Biotherapeutics — Investor Presentation (September 2021)
30 slides from Sensei Biotherapeutics's investor presentation, Sep 8, 2021
Slide 1: Training the Immune System to Fight Cancer
August 4, 2021 Training the Immune System to Fight Cancer John K. Celebi, MBA President & Chief Executive Officer September 8, 2021 Exhibit 99.1
Slide 2: Disclaimer and forward-looking statements
This presentation has been prepared by Sensei Biotherapeutics, Inc. (the “Company,” "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as o
Slide 3: Two Platforms to Unleash Anti-Cancer T-cell Activity
Generate anti-tumor T-cells Unleash anti-tumor T-cells ImmunoPhage™ Platform Powerfully self-adjuvanted nanoparticle vaccine can drive B cell and T cell responses Multi-antigen vaccine enables personalized approach from “off-the-shelf” components Targets APCs Enhanced through addition of immunostimu
Slide 4: T-Cells Are Central to Our Approach
T cell APC Peptide TCR HLA T cell Immune Checkpoint Focus on multi-antigen approach for HLA-mediated immunotherapy to GENERATE anti-tumor T-cells ImmunoPhage™ TMAb Target Cell Focus on novel immune checkpoints to UNLEASH anti-tumor T-cells T-Cells Are Central to Our Approach and the Key to Unlocking
Slide 5: Positioned to Drive Value with Next Generation Product & Platform Development
Two Platforms Provide Broad Pipeline Opportunities TMAb* Platform ImmunoPhage™ Platform *Tumor Microenvironment Activated biologics In-house GMP manufacturing capabilities Business Development Strong Cash Position Positioned to Drive Value with Next Generation Product & Platform Development
Slide 6: Pipeline Utilizing Pioneering ImmunoPhage Platform, TMAb Platform
Pipeline Utilizing Pioneering ImmunoPhage Platform, TMAb Platform Program (Target) Indication Discovery IND-enabling Phase 1 / 2 Clinical TMAb SNS-101 (VISTA) Solid Tumors SNS-VSIG4 Solid Tumors ImmunoPhage SNS-401-NG (Multiple Tumor Antigens) Merkel Cell Carcinoma Head and Neck Cancer Lung Cancer M
Slide 7: TMAb Platform
TMAb (Tumor Microenvironment Activated biologics) Platform
Slide 8: pH-sensitive Antibodies Only Bind Targets in the Low-pH Tumor Microenvironment
Antibodies that bind at physiological pH may encounter a “sink” Prevents effective binding at the tumor and may lead to toxicity TMAb antibodies bypass tissue compartments other than the low-pH tumor microenvironment Potential for improved safety and clinical activity profile pH 7.4 pH 7.4 pH 7.4 pH
Slide 9: Why a pH-sensitive Antibody is Important
Joshi et al, Journal of Clinical Pharmacology, 2006 TMAb Platform Antibodies that bind at physiological pH may result in rapid elimination from circulation through targeted-mediated drug disposition (TMDD) In such cases, efficacious drug occupancy levels may be difficult to reach, potentially narrow
Slide 10: ImmunoPhage Platform
ImmunoPhage™ Platform
Slide 11: Bacteriophage
Ubiquitous viruses that infect bacteria but not mammalian cells. Adept at activating the human immune system in multiple unique ways Bacteriophage
Slide 12: ImmunoPhage Platform Generating Strong Antibody and T-cell Responses
ImmunoPhage Platform Generating Strong Antibody and T-cell Responses Bacteriophage virus is engineered and manufactured with both antigen and immune stimulatory viral DNA Viral DNA (self-adjuvant) Target antigen The ImmunoPhage™ bacteriophage is an icosahedron with a tail. This configuration can be
Slide 13: Generating Strong Antibody and T-cell Responses
Generating Strong Antibody and T-cell Responses ImmunoPhages are taken-up by APCs and deliver three critical signals required to drive activation of T cells. Antigen cross presentation Positive co-stimulation Generation of Th1-biased immune response & cytokines CD28 CD80 T cell receptor Antigen T- C
Slide 14: ImmunoPhage: A Multi-Pronged Approach to Address the Complexities of Cancer
Our ImmunoPhages can mount a multi-modal attack on cancer, combining the benefits of a traditional vaccine with localized gene therapy Targeted therapeutic vaccine MHC-mediated immunity Bacteriophage have natural tropism for APCs Can be further targeted to APCs with non-antigen capsid modifications
Slide 15: Pipeline Programs
Pt NSE} Pipeline Programs = % SENSE! 3% 9 BIOTHERAPEUTI
Slide 16: VISTA is a Negative Regulator of T cell Function
1 Lines et al. Cancer research vol. 74,7 (2014) 2 Gao et al. Nature medicine vol. 23,5 (2017) VISTA: An Emerging Checkpoint Target on Myeloid Cells First TMAb™ program against VISTA B7 family ligand Expressed on myeloid cells, macrophages, NK cells and T-regs1 Inhibition of VISTA may lead to activat
Slide 17: Increased Understanding of VISTA as a Promising Target
Increased Understanding of VISTA as a Promising Target to Address the Needs of Patients with Cancer
Slide 18: VISTA Checkpoint is Activated at the Low pH of the Tumor Microenvironment
VISTA’s extracellular domain is uniquely rich in histidines¹ Histidines are protonated at low pH enabling VISTA to distinguish the active (acidic pH) and inactive (neutral pH) PSGL-1 binding interface 1. Johnston et al., Nature 2019 VISTA Checkpoint is Activated at the Low pH of the Tumor Microenvir
Slide 19: Anti-VISTA Programs in Development
TMAb Platform Anti-VISTA Programs in Development BMS Kineta CI-8993 (formerly JNJ-61610588) PF-W0180 HMBD-002 pH Sensitivity Yes Yes No No No No Stage Preclinical Preclinical Preclinical Phase I Phase I Phase I Clinical Data / Notes Preclinical data to be presented by year-end 2021 IND-enabling stud
Slide 20: pH-Sensitive Anti-VISTA Antibodies Showed Positive Results In Vivo
Sensei Anti-VISTA Parental mAb Tumor Growth of MC38 in Hu VISTA Knock-in Mice SNS-101 is pH-Sensitive Dosing: 14d @ 20mpk q3d Anti-PD-1 + anti-VISTA Anti-PD-1 Control >600-fold selectivity for pH 6.0 Significant binding occurs at low pH No significant binding observed at physiological pH (7.4) pH-Se
Slide 21: VSIG4: A Novel Next Generation Checkpoint
Second TMAb program B7 family related protein Expressed on macrophages Inhibits T-cell activation Novel therapeutic combinability with existing IO drugs Adapted from Zang et al., J Clin Invest. 2006 VSIG4: A Novel Next Generation Checkpoint Modulating the Tumor Microenvironment No approved therapies
Slide 22: SNS-401-NG: Building the First Custom MCPyV ImmunoPhage
33-46% disease-specific mortality 2,500 cases/yr with disease-specific mortality approaching 50% Vaccine combination therapy in adjuvant or neoadjuvant is attractive and feasible PD-1/PD-L1 refractory MCC remains unmet medical need with aggressive clinical course ~40% MCC patients recur <24 months f
Slide 23: Mechanism of Action: Activation and Maturation of Dendritic Cells
Critical signals of dendritic cell activation show dose-dependent increases when cells are exposed to increasing amounts of ImmunoPhages Mechanism of Action: Activation and Maturation of Dendritic Cells Dose-response of engineered lambda phage on human skin-derived DC cultures Signal: Dendritic cell
Slide 24: SNS-401-NG Development in Merkel Cell
SNS-401-NG Development in Merkle Cell 1. Based on internal data SNS-401-NG has Potential to be First Fully Customized, Yet Off-the-Shelf, Therapy Common Tumor Antigens + MCPyV+ MCC tumors Immunophage expressing MCPyV B- and T-cell antigens Routine Biopsy Tumor Sequencing Immunophage expressing tumor
Slide 25: Phortress: Proprietary Library of Personalized Vaccine Cocktails
These “cocktails” are defined by the disease or patient genetics Combinations are customized to cover multiple epitopes, protein domains or targets Each ImmunoPhage is pre-manufactured to target a discrete antigen Cancer Bacteriophage l Genetically engineered bacteriophages each expressing distinct
Slide 26: Personalized Immunotherapy Approach Could Accelerate Speed to Treatment
Neoantigen Prediction Neoantigen ImmunoPhage️ Manufacturing ImmunoPhage Injection Including Neoantigens Deliver neoantigen ImmunoPhage️ cocktail for administration and add neoantigen phages to bank for future use Identify additional tumor specific neoantigens Engineer novel ImmunoPhages️ expressing
Slide 27: Sensei's Vision to Capture Platform and Pipeline Value
Sensei’s Vision to Capture Platform and Pipeline Value 2016 Measured investments in platform Advanced first program into clinic Absorb key learnings and refine technology 2021 Feb 2021: IPO 2026 Focus on Platform Innovation and New INDs Invest in Manufacturing and Supply Chain Commercial Capabilitie
Slide 28: Proven Team With Deep Experience
Michael Boychyn, PhD SVP, CMC Jean Campbell, PhD VP, Biologics Discovery Bao Le VP, Regulatory John Celebi, MBA President and CEO Marie-Louise Fjaellskog, MD, PhD Chief Medical Officer Robert Pierce, MD Chief Scientific Officer Proven Team With Deep Experience Erin Colgan SVP, Finance and Administra
Slide 29: Upcoming Expected Program Milestones
Upcoming Expected Program Milestones SNS-101 (anti-VISTA) YE 2021: Present preclinical data at scientific meeting Select lead candidate Initiate IND-enabling studies SNS-401-NG 2H 2022: initiate IND-enabling studies SNS-VSIG4 2023: Select product candidate
Slide 30: Training the Immune System to Fight Cancer
August 4, 2021 Training the Immune System to Fight Cancer John K. Celebi, MBA President & Chief Executive Officer September 8, 2021
Sensei Biotherapeutics — Investor Presentation (September 2021) on 6ix